# 2025-04046: Clinical Firm Seeks DEA Nod for Marijuana Imports

2025-04046, Importer of Controlled Substances Application: Fisher Clinical Services, Inc., is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-03-13, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 14, 2025. Such persons may also file a written request for a hearing on the application on or before April 14, 2025.; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04046
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04046
- Title: Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 11997
- Published: 2025-03-13
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 14, 2025. Such persons may also file a written request for a hearing on the application on or before April 14, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

Clinical Firm Seeks DEA Nod for Marijuana Imports

## Summary

Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and related compounds. People and companies already registered can comment or object by April 14, 2025, and even request a hearing. This move could impact businesses dealing with these substances and involves a formal review process with deadlines to keep in mind.

## Abstract

Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Application to Import Three Schedule I Drugs: benefit, low. On January 29, 2025, Fisher Clinical Services, Inc. applied to be registered to import these Schedule I controlled substances: marihuana (drug code 7360), tetrahydrocannabinols (drug code 7370), and 5‑Methoxy‑N,N‑dimethyltryptamine (drug code 7431). The company says it plans to import these listed…
- No Import of Finished Dosage Forms for Sale: cost, low. The DEA notice says authorization will not extend to the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. The registration, if granted, is limited to the listed drug codes and uses.
- Comment and Hearing Deadline for Affected Registrants: benefit, low. Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before April 14, 2025 via Regulations.gov or the DEA hearing addresses provided in the notice.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-04046 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/13/2025-04046/importer-of-controlled-substances-application-fisher-clinical-services-inc)
- [2025-04046 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04046.pdf)

## Related
- [Previous: 2025-04045, Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals…](https://policyrisk.com/federal-register/2025-04045)
- [Next: 2025-04060, Notice of Request for Public Comments on Section 232 National Security Investig…](https://policyrisk.com/federal-register/2025-04060)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04046 (as of 2026-09-30).
